Event
FDA Convening
Evaluating the Pressor Effects of Drugs & Ambulatory Blood Pressure Monitoring Studies
RegisterMaterials
duke-fda_pressor_agenda_updated_2019-02-05.pdf (210.7 KB)duke-fda_pressor_biographies_updated_2019-02-05.pdf (475.27 KB)
duke-fda_pressor_slides_updated_2019-02-05.pdf (5.75 MB)
Workshop Description
The U.S. Food and Drug Administration (FDA) is announcing a public workshop entitled “Evaluating the Pressor Effects of Drugs & Ambulatory blood pressure Monitoring Studies.” This public workshop is convened by the Duke-Robert J. Margolis, MD, Center for Health Policy at Duke University and supported by a cooperative agreement with FDA. The purpose of this public workshop is to bring the stakeholder community together to discuss the premarketing assessment of a drug's effect on blood pressure. Elevated blood pressure is known to increase the risk of stroke, heart attack, and death. The effect of a drug on blood pressure may therefore be an important consideration in benefit-risk assessment.
Duke-Margolis Team

Nicholas R. Harrison, MPH, MA
Policy Research Associate